Relationship Between BMI and Disease Severity in COVID-19 Patients

Meisam Moezzi, Mandana Ghanavati, Mozhan Heydarnezhad, Elham Farhadi and Ali Reza Rafati Navaei

1 Department of Emergency Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Clinical Research Development Unit, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Emergency Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: ali_rafaty@yahoo.com

Received 2022 July 15; Accepted 2022 September 16.

Abstract

Background: Obesity and increased body mass index (BMI) are associated with coronavirus disease 2019 (COVID-19)-related complications and severity. They can exacerbate the cytokine storm and lead to severe symptoms or death in obese patients.

Objectives: This cross-sectional descriptive study included patients with COVID-19 admitted to the Razi Hospital in Ahvaz, Iran, from January 2019 to December 2020.

Methods: We evaluated the effect of BMI of patients admitted to the general ward and invasive unit care (ICU) on the length of hospitalization.

Results: We included a total of 466 patients (male: 281 or 60.3% vs. female: 185 or 39.7%) with a mean age of 59.49 ± 14.5 years in the study. Also, 47 (10.1%) patients were admitted to the ICU, and 418 (89.7%) patients to the general ward. A higher BMI was associated with longer hospitalization (P < 0.001). Patients with BMI in the range of 18.5 - 24.9 experienced a longer hospitalization (10-20 days) (P < 0.001). BMI had no significant effect on ICU hospitalization (P = 0.36). Also, there was no significant difference between the two groups regarding the length of hospitalization (P = 0.49). Furthermore, non-diabetic patients were less likely to be admitted to the ICU (73.3% vs. 26.7%) (P < 0.001). The number of discharged patients was higher in patients admitted to the general ward compared to those admitted to the ICU (93.8% vs. 63.8%) (P < 0.001).

Conclusions: According to our results, a higher BMI was a risk factor for COVID-19, especially in the early stage of infection.

Keywords: COVID-19, Obesity, BMI, Hospitalization

1. Background

The outbreak of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was announced by World Health Organization (WHO) as a global epidemic on March 11, 2020. The disease has spread rapidly throughout China and many other countries since its first appearance in Wuhan, China, in December 2019 (1).

COVID-19 increases inflammation by triggering a cytokine storm and has a high mortality rate with many complications, such as severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Cytokines are central regulators of the immune system, and increased production of inflammatory cytokines leads to deregulation of the immune system (2, 3).

Increased fat cells contribute to the exacerbation of the cytokine storm. Increased body fat leads to the accumulation of excess metabolic byproducts of obesity in obese people and activates inflammatory signaling pathways similar to infection (4). In addition, high leptin level in obese people increases inflammation (5). Many studies have also identified obesity as a risk factor for COVID-19 patients (6-8). Obesity leads to an irregular immune response to respiratory infections (9). Researchers believe that obesity and increased body fat can exacerbate the cytokine storm and lead to severe symptoms or death in obese patients (10). Obesity also has a significant impact on normal lung function. Fat deposits alter the mechanics of the lungs, thus reducing lung compliance (11).

Body mass index (BMI) is used to classify obesity. BMI is calculated as the weight ratio in kilograms to height squared in meters, expressed in kilograms per square meter (12). BMI above 30 and obesity are associated with poor outcomes, including invasive unit care (ICU) admission, acute respiratory distress syndrome (ARDS), severe COVID-19, use of mechanical ventilation, hospitalization, and mortality in adult COVID-19 patients (13). Thus, obesity can increase the complications associated with COVID-19.
2. Objectives

In this study, we evaluated the relationship between the hospitalization length of COVID-19 patients with BMI. We also assessed the effect of obesity on COVID-19 severity.

3. Methods

3.1. Study Population

This cross-sectional descriptive study included patients with COVID-19 admitted to the general ward and ICU of Razi Hospital in Ahvaz, Iran, from January 2019 to December 2020. Inclusion criteria were definitive diagnosis of COVID-19 by the reverse transcription polymerase chain reaction (RT-PCR) or detection of lung involvement by computed tomography (CT) scan. Outpatients and patients with incomplete data were excluded from the study.

The Research Ethics Board of xxx University of Medical Sciences approved the study protocol (IR.AJUMS.REC.1399.937), and a written informed consent was obtained from all patients.

3.2. Data Collection

We recorded the patients’ demographic and clinical data, including age, sex, BMI, underlying disorders, and length of hospitalization.

3.3. Statistical Analysis

In quantitative variables, mean or median and standard deviation (SD) or interquartile range (IQR) were used. In qualitative variables, frequency and percentage were used to describe data. The normality of the data was evaluated using the Kolmogorov-Smirnov test and Q-Q diagram. All analyses were performed using the Statistical Package for the Social Sciences (SPSS) software version 20. The significance level was considered as P < 0.05.

4. Results

4.1. Study Population

The present study included 466 patients, including 281 (60.3%) males and 185 (39.7%) females. The mean age was 59.49 ± 14.5 years. Also, 47 (10.1%) patients were admitted to the ICU, and 418 (89.7%) patients to the general ward (Table 1). The mean hospitalization length was 14.5 ± 6.8 days. All patients were categorized based on their BMI into six subgroups, including < 18.5, 18.5 - 24.9, 25 - 29.9, 30 - 34.9, 35 - 39.9, and > 40. The BMI of most patients (37.3%) was in the range of 18.5 - 24.9, followed by 25 - 29.9 (22.3%), 35 - 39.9 (13.1%), and 30 - 34.9 (12.4%) (Table 1). At the end of the study, 9.2% of patients died.

| Variables | Frequency (%) |
|-----------|---------------|
| Gender    |               |
| Male      | 281 (60.3)    |
| Female    | 185 (39.7)    |
| Hospitalization |   |
| General section | 418 (99.7) |
| ICU       | 47 (10.1)     |
| BMI       |               |
| < 18.5    | 16 (3.4)      |
| 18.5 - 24.9 | 174 (37.3)  |
| 25 - 29.9 | 104 (23.3)    |
| 30 - 34.9 | 58 (12.4)     |
| 35 - 39.9 | 61 (13.1)     |
| > 40      | 53 (11.4)     |
| Survival  |               |
| Expired   | 43 (9.2)      |
| Discharged| 422 (90.6)    |

4.2. The Association Between BMI and Hospitalization

A higher BMI was associated with higher length of hospitalization (P < 0.001). Based on our results, patients with BMI in the range of 18.5-24.9 experienced a longer hospitalization (10 - 20 days) (Table 2). However, no association was found between BMI with noninvasive ventilation (NIV) and intubation (P > 0.05) (Table 2). The death rate was higher in patients with BMI in the range of 18.5 - 24.9; however, there was no significant difference (P = 0.74). In our study, patients > 59 and < 59 were the same for BMI, and there was no significant difference (P = 0.37).

4.3. The Association Between BMI and ICU Admission

BMI had no significant effect on the rate of ICU admission (P = 0.36) (Also, Also, there was no significant difference between the two groups regarding the length of hospitalization (P = 0.49) (Table 3). Non-diabetic patients were less likely to be admitted to the ICU (73.3% vs. 26.7%) (P < 0.001). Furthermore, the number of discharged patients was higher in patients admitted to the general ward compared to ICU admissions (93.8% vs. 63.8%) (P < 0.001) (Table 3).

5. Discussion

Recognizing the associated risk factors with COVID-19 hospitalization reduces the mortality rate and cost of care.
Table 2. The Influence of BMI on the COVID-19 Progression and Treatment

| Variables                  | BMI                  | P-Value |
|----------------------------|----------------------|---------|
|                            | < 18.5 | 18.5 - 24.9 | 25 - 29.9 | 30 - 34.9 | 35 - 39.9 | > 40 |< 0.001 |
| **Length of hospitalization (d)** |         |           |           |           |           |       |
| < 10                       | 6 (4.1) | 40 (27.6) | 39 (26.9) | 20 (13.8) | 27 (18.6) | 13 (9) |
| 10 - 20                    | 7 (2.8) | 116 (46.4) | 53 (21.2) | 26 (10.4) | 28 (11.2) | 20 (8) |
| > 20                       | 3 (4.2) | 18 (25.4) | 12 (16.9) | 12 (16.9) | 6 (8.5) | 20 (28.2) |
| **NVI**                    |         |           |           |           |           |       |
| Yes                        | 1 (4.8) | 9 (42.9) | 3 (14.3) | 1 (4.8) | 5 (23.8) | 2 (9.5) |
| No                         | 15 (3.4) | 165 (37.1) | 101 (22.7) | 57 (12.8) | 56 (12.6) | 51 (11.5) |
| **Intubation**             |         |           |           |           |           | 0.38   |
| Yes                        | 0 | 9 (39.1) | 1 (4.3) | 5 (21.7) | 5 (21.7) | 3 (13) |
| No                         | 16 (3.6) | 164 (37.1) | 103 (23.3) | 53 (12) | 56 (12.7) | 50 (11.3) |
| **Survival**               |         |           |           |           |           | 0.74   |
| Death                      | 2 (4.7) | 12 (27.9) | 10 (23.3) | 5 (11.6) | 8 (18.6) | 6 (14) |
| Alive                      | 14 (3.3) | 161 (38.2) | 94 (22.3) | 53 (12.6) | 53 (12.6) | 47 (11.1) |

\(^a\) Values are expressed as No. (%).
### Table 3. Comparing Two Groups for Influencing Factors in ICU Admission

| Variables                  | ICU Hospitalization | Total | PValue |
|----------------------------|---------------------|-------|--------|
|                            | Yes | No   |       |        |
| **BMI**                    |     |      |       |        |
| < 18.5                     | 1 (2.1) | 15 (3.6) | 16 (3.4) | 0.36   |
| 18.5 - 24.9                | 19 (40.4) | 154 (36.8) | 173 (37.2)  |
| 25 - 29.9                  | 5 (10.6) | 99 (21.7) | 104 (22.4)  |
| 30 - 34.9                  | 7 (14.9) | 51 (12.2) | 58 (12.5)   |
| 35 - 39.9                  | 7 (14.9) | 54 (12.9) | 61 (13.1)   |
| > 40                       | 8 (17) | 45 (10.8) | 53 (11.4)   |
| **Length of hospitalization (d)** |     |      |       | 0.49   |
| < 10                       | 11 (23.4) | 131 (31.8) | 144 (31)    |
| 10 - 20                    | 28 (59.6) | 222 (53.1) | 250 (53.8)  |
| > 20                       | 8 (17) | 61 (15.1) | 71 (15.3)   |
| **Gender**                 |     |      |       | 0.17   |
| Male                       | 24 (51.1) | 256 (61.2) | 280 (60.2)  |
| Female                     | 23 (48.9) | 162 (38.8) | 185 (39.8)  |
| **Hypertension**           |     |      |       | 0.26   |
| Yes                        | 15 (31.9) | 102 (24.4) | 117 (25.2)  |
| No                         | 32 (68.1) | 316 (75.6) | 348 (74.8)  |
| **Diabetes**               |     |      |       | 0.023  |
| Yes                        | 6 (12.8) | 118 (28.2) | 124 (26.7)  |
| No                         | 41 (87.2) | 300 (71.8) | 341 (73.3)  |
| **Hyperlipidemia**         |     |      |       | 0.92   |
| Yes                        | 1 (2.1) | 8 (1.9) | 9 (1.9)   |
| No                         | 46 (97.9) | 410 (98.1) | 456 (98.1)  |
| **Cardiovascular disease** |     |      |       | 0.67   |
| Yes                        | 2 (4.3) | 13 (3.1) | 15 (3.2)   |
| No                         | 45 (95.7) | 405 (96.9) | 450 (96.8)  |
| **Smoking**                |     |      |       | 0.11   |
| Yes                        | 2 (4.3) | 50 (12) | 52 (11.2)  |
| No                         | 45 (95.7) | 368 (88) | 413 (88.8)  |
| **Liver dysfunction**      |     |      |       | 0.28   |
| Yes                        | 0 | 10 (2.4) | 10 (2.2)   |
| No                         | 47 (100) | 408 (97.6) | 455 (97.8)  |
| **Kidney disorder**        |     |      |       | 0.16   |
| Yes                        | 5 (10.6) | 23 (5.5) | 28 (6)    |
| No                         | 42 (89.4) | 395 (94.5) | 437 (94)   |
| **Rheumatism**             |     |      |       | 0.65   |
| Yes                        | 1 (2.1) | 14 (3.3) | 15 (3.2)   |
| No                         | 46 (97.9) | 404 (96.7) | 450 (96.8)  |
| **Cancer**                 |     |      |       | 0.47   |
| Yes                        | 1 (2.1) | 18 (4.3) | 19 (4.1)   |
| No                         | 46 (97.9) | 400 (95.7) | 446 (95.9)  |
| **Brain stork**            |     |      |       | 0.92   |
| Yes                        | 1 (2.1) | 8 (1.9) | 9 (1.9)    |
| No                         | 46 (97.9) | 410 (98.1) | 456 (98.1)  |
| **NIV**                    |     |      |       | 0.45   |
| Yes                        | 3 (6.4) | 17 (4.1) | 20 (4.3)   |
| No                         | 44 (93.6) | 401 (95.9) | 445 (95.7)  |
| **Survival**               |     |      |       | < 0.001|
| Death                      | 17 (36.2) | 26 (6.2) | 43 (9.2)  |
| Alive                      | 30 (63.8) | 392 (93.8) | 422 (90.8)  |
ICU.

The limitation of the present study was the lack of data about the vaccination status of participants, including the number of injections, type of vaccine, and the interval between infection and last dosage of vaccine. Evaluating adverse events of COVID-19 with the level of BMI is highly recommended.

5.1. Conclusions

The current survey evaluated the impact of BMI on ICU admission in patients with COVID-19. Our data demonstrated that high BMI is a risk factor for COVID-19, especially in the early stage of infection.

Acknowledgments

We thank all the staff in the Allied Health Sciences School, Ahvaz Jundishapur University of Medical Sciences, Iran.

Footnotes

Authors’ Contribution: ARN, MM, and MG designed the study, analyzed the original surveys' data, and created the first draft of the manuscript. MH and EF reviewed the data interpretation from the original studies and contributed to manuscript revisions. All authors have read and approved the manuscript.

Conflict of Interests: The authors declare that they have no competing interests.

Ethical Approval: The Research Ethics Board of Ahvaz Jundishapur University of Medical Sciences, Iran, approved the study protocol (IR.AJUMS.REC.1399.937).

Funding/Support: The authors received no funding or support for this study.

Informed Consent: Written informed consent was obtained from all patients.

References

1. Soeroto AY, Soetedjo NN, Purwiga A, Santoslo P, Kulidum S, Suryadinata H, et al. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(6):1897-904. [PubMed ID: 33007661]. [PubMed Central ID: PMC7521380]. https://doi.org/10.1016/j.dsx.2020.09.029.
2. Najafi S, Rajaei E, Moallemlan R, Nokhostin F. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol. 2020;39(11):3223–35. [PubMed ID: 32885345]. [PubMed Central ID: PMC7475410]. https://doi.org/10.1007/s10067-020-05376-x.
3. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology. 2020;291(1):38. [PubMed ID: 32003646]. [PubMed Central ID: PMC794019]. https://doi.org/10.1485/rd.2020.202036.
4. Ramos Muniz MG, Palfreeman M, Setzu N, Sanchez MA, Saenz Portillo F, Garza KM, et al. Obesity Exacerbates the Cytokine Storm Elicited by Francisella tularensis Infection of Females and Is Associated with Increased Mortality. Biomed Res Int. 2018;2018:3412732. [PubMed ID: 30046592]. [PubMed Central ID: PMC6038682]. https://doi.org/10.1155/2018/3412732.
5. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am. 2008;37(3):753–68, xxi. [PubMed ID: 18775162]. [PubMed Central ID: PMC2659415]. https://doi.org/10.1016/j.ecl.2008.07.002.
6. Korakas E, Ekonomidou I, Kousathana F, Balamanakis K, Kountouri A, Raptis A, et al. Obesity and COVID-19: immune and metabolic dereg-ament as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metab. 2020;319(1):E105–9. [PubMed ID: 32459524]. [PubMed Central ID: PMC7322584]. https://doi.org/10.1152/ajpendo.00988.2020.
7. Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Krisko T, et al. Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City. Obesity (Silver Spring). 2020;28(9):1606–12. [PubMed ID: 32470201]. [PubMed Central ID: PMC7283843]. https://doi.org/10.1002/oby.23245.
8. Friedman AN, Guirguis J, Kapoor R, Gupta S, Leaf DE, Timsina LR, et al. Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US. Obesity (Silver Spring). 2021;29(10):1799–30. [PubMed ID: 34109768]. https://doi.org/10.1002/oby.23245.
9. Kulsar KA, Coleman CM, Beck SE, Frieden MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4(20). [PubMed ID: 31550243]. [PubMed Central ID: PMC6824443]. https://doi.org/10.1172/jci.insight.131774.
10. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis. 2020;71(5):396–7. [PubMed ID: 32273668]. [PubMed Central ID: PMC7184372]. https://doi.org/10.1093/cid/ciaa455.
11. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755–67. [PubMed ID: 30056777]. [PubMed Central ID: PMC6131835]. https://doi.org/10.1080/1478924X.2018.1506331.
12. Prentice AM, Jebb SA. Beyond body mass index. Obes Rev. 2001;2(3):141–7. [PubMed ID: 12200999]. https://doi.org/10.1046/j.1467-789X.2001.00031.x.
13. Kim TS, Roslin M, Wang J, Kane J, Hirsch JS, Kim EJ, et al. BMI as a Risk Factor for Clinical Outcomes in Patients Hospitalized with COVID-19 in New York. Obesity (Silver Spring). 2021;29(2):279–84. [PubMed ID: 33128848]. [PubMed Central ID: PMC8191573]. https://doi.org/10.1002/oby.23076.
14. Bhasin A, Nam H, Yeh C, Lee J, Liebovitz D, Achenbach C. Is BMI Higher in Younger Patients with COVID-19? Association Between BMI and COVID-19 Hospitalization by Age. Obesity (Silver Spring). 2020;28(10):1811–4. [PubMed ID: 32603756]. [PubMed Central ID: PMC7609443]. https://doi.org/10.1002/oby.22947.
15. Mohseni H, Amini S, Abiri B, Kalantar M. Do body mass index (BMI) and history of nutritional supplementation play a role in the severity of COVID-19? A retrospective study. Nut Food Sci. 2021;51(6):1017–27. https://doi.org/10.1080/nfs.1-2020-0421.
16. Pranata R, Lim MA, Huang I, Yonas E, Henrina J, Vania R, et al. Visceral adiposity, subcutaneous adiposity, and severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. Clin Nutr ESPEN. 2021;43:163–8. [PubMed ID: 34024509]. [PubMed Central ID: PMC8032475]. https://doi.org/10.1016/j.clnesp.2021.04.001.

17. Aboudounya MM, Heads RJ. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. Mediators Inflamm. 2021;2021:8874339. [PubMed ID: 33505220]. [PubMed Central ID: PMC7811571]. https://doi.org/10.1155/2021/8874339.

18. Liu A, Chen M, Kumar R, Stefanovic-Racic M, O'Doherty RM, Ding Y, et al. Bone marrow lympho-myeloid malfunction in obesity requires precursor cell-autonomous TLR4. Nat Commun. 2018;9(1):1–11. [PubMed ID: 29453396]. [PubMed Central ID: PMC5816016]. https://doi.org/10.1038/s41467-018-03145-8.

19. Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences in ICU admissions during the first and second COVID-19 wave in Germany. Lancet Respir Med. 2021;9(5):e47–8. [PubMed ID: 33684356]. [PubMed Central ID: PMC8078895]. https://doi.org/10.1016/S2213-2600(21)00104-6.